

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email doh.information@doh.wa.gov.

January 17, 2025
Weekly Legislative Review Agenda

Time: 12:00 p.m. – 1:00 p.m.
Location: Zoom ID: **890 1330 6617**
<https://us02web.zoom.us/j/89013306617>
Or One tap mobile :
+12532050468,,89013306617# US
+12532158782,,89013306617# US (Tacoma)
<https://zoom.us/join>
Webinar ID: 890 1330 6617
In Person: Department of Health, TC2
[111 Israel Rd SE, Rm. 140](#)
[Tumwater, WA 98501](#)
Contact: Joshua Munroe, Rules and Legislative Consultant, 360.502.5058
Joshua.Munroe@doh.wa.gov
Commission Office: wspqac@doh.wa.gov

No registration needed. **All attendees will join the call with their audio connection muted.**

12:00 p.m.

1. Call to Order
 - 1.1. Roll Call
2. PQAC Bill Report
3. Public Comment Period

Meeting Adjourned

[Link to Washington State Legislature Bill Information 2025](#)

Monday, January 13 – First day of session
 Friday, February 21 – Policy committee cutoff **Next cutoff**
 Friday, February 28 – Fiscal committee cutoff
 Wednesday, March 12 – House of origin cutoff
 Wednesday, April 2 – Policy committee cutoff (opposite house)

Tuesday, April 8 – Fiscal committee cutoff (opposite house)
 Wednesday, April 16 – Opposite house cutoff
 Sunday, April 27 – Sine die: Last day allowed for regular session under state constitution

TVW - <http://www.tvw.org/>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
HB 1009	Membership of the Pharmacy Quality Assurance Commission	HB 1009 amends RCW 18.64.001 pertaining to individual eligibility to apply for a seat on the Pharmacy Quality Assurance Commission (commission). The bill changes one of the seats reserved only for a licensed pharmacist to allow for a public member who “may be an owner, officer, or operator of a pharmacy, but may not be licensed as a pharmacist or pharmacy technician” to also apply for the seat.	<p>HB 1009 <i>Sponsor(s):</i> Representatives Low, Ramel, and Eslick</p> <p><i>Pre-filed:</i> 12/4/2024 <i>First Reading (House):</i> 1/13/2025, referred to Health Care & Wellness Committee. <i>Public Hearing (Health Care & Wellness):</i> 1/15/2025 <i>Executive Session (Health Care & Wellness):</i> 1/17/2025</p>
SB 5019	Prepackaged medication distribution	<p>RCW 70.41.480 relates to prepackaged medications in an emergency department. RCW 70.41.480(3) creates restrictions for a practitioner or registered nurse to distribute prepackaged emergency medications to patients upon discharge. Effective January 1, 2025, these restrictions include no more than a 48 hour supply that can be dispensed to a patient except when:</p> <ul style="list-style-type: none"> community or hospital pharmacy services will not be available within 48 hours; or human immunodeficiency virus postexposure prophylaxis (HIV PEP) drugs or therapies are required. 	<p>SB 5019 <i>Sponsor(s):</i> Senator Chapman</p> <p><i>Pre-filed:</i> 12/9/2024 <i>First Reading (Senate):</i> 1/13/2025, referred to Health & Long-Term Care Committee.</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
		<p>SB 5019 amends these exceptions to the 48-hour dispensing limit to include when anti-infective drugs or therapies are required or when drugs or therapies are packaged directly by the manufacturer in quantities larger than 48 hours, in addition to the above list.</p> <p>The bill also amends RCW 18.64.450 to allow health care entities (HCEs) to dispense and deliver legend drugs and controlled substances beyond the 72-hour limit in the following situations:</p> <ul style="list-style-type: none"> • Community or hospital outpatient pharmacy services will not be available within 72 hours; • Anti-infectives or human immunodeficiency virus postexposure prophylaxis (HIV PEP) drugs; or • Drugs or therapies packaged directly by the manufacturer for a period longer than a 48-hour period. 	
<u>HB 1186</u>	Prepackaged medication distribution	Companion bill to SB 5019.	<p><u>HB 1186</u> <i>Sponsor(s):</i> Representatives Parshley, Rule, Low, Reed, Ramel, Macri, Obras, Farivar, Doglio, Fosse, Ormsby, Salahuddin, Bernbaum, and Hill</p> <p><i>Pre-filed:</i> 1/7/2025 <i>First Reading (House):</i> 1/13/2025, referred to Health Care & Wellness Committee.</p>
<u>HB 1124</u>	Psychologist prescriptive	HB 1124 amends chapter 18.83 RCW to establish a certification for prescribing psychologists. The bill authorizes prescribing psychologists to	<u>HB 1124</u>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
	authority certification	prescribe, administer, discontinue, and distribute controlled substances to treat mental illnesses. The bill also amends the definition of practitioner in RCW 18.64.011 to include prescribing psychologists.	<p><i>Sponsor(s)</i>: Representatives Simmons, Macri, Senn, Stonier, Ormsby, Tharinger, Kloba, Duerr, Ryu, Morgan, Reed, Callan, Obras, Doglio, Ortiz-Self, Goodman, Reeves, and Hill</p> <p><i>Pre-filed</i>: 12/23/2024 <i>First Reading (House)</i>: 1/13/2025, referred to Health Care & Wellness Committee.</p>
SB 5201	Access to psychedelic substances	<p>This bill establishes wellness model-based psilocybin services and establishes DOH and LCB authority to license, regulate, and enforce all provisions. Psilocybin can only be administered to a person 21 years of age or older in an approved setting, under the supervision of a licensed psilocybin facilitator or clinical facilitator. The program development period is designated from September 1, 2025 to September 1, 2027, during which DOH is to establish a Psychedelic Substances Board to advise DOH, conduct rulemaking, and establish educational trainings and exams.</p> <p>DOH must establish rules regarding qualifications, licensing and renewals, fees, education and training, substantially equivalent qualifications, testing, scope of practice, and other regulations specified in the bill for multiple new professions and facilities. DOH must also establish rules for defining “approved supervisor” qualification requirements, authorized disclosure of protected client information, and other requirements outlined in the bill. Rules must be adopted and forms established by October 31, 2027. DOH must begin receiving applications November 1, 2027.</p> <p>“Psychedelic substance” is defined as psilocybin until the end of 2029.</p>	<p><u>SB 5201</u></p> <p><i>Sponsor(s)</i>: Senators Salomon, Nobles, Bateman, Trudeau, Lovelett, Frame, Chapman, Hasegawa, and Wellman</p> <p><i>Pre-filed</i>: 1/9/2025 <i>First Reading (Senate)</i>: 1/13/2025, referred to Health & Long-Term Care Committee.</p>

Agency Request Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
HB 1034	Nonopioid drugs for the treatment of pain	<p>HB 1034 <i>Sponsor(s):</i> Representatives Ortiz-Self and Peterson</p> <p><i>Pre-filed:</i> 12/11/2024 <i>First Reading (House):</i> 1/13/2025, referred to Health Care & Wellness Committee. 120</p>
HB 1209	Transfer of sodium nitrite	<p>HB 1209 <i>Sponsor(s):</i> Representatives Mena, Walen, Reed, Ryu, Berry, Alvarado, Macri, Farivar, Doglio, Pollet, Ormsby, Salahuddin, and Hill</p> <p><i>Pre-filed:</i> 1/9/2025 <i>First Reading (House):</i> 1/13/2025, referred to Consumer Protection & Business Committee. <i>Public Hearing (Consumer Protection & Business Committee):</i> 1/17/2025</p>
SB 5178	Transfer of sodium nitrite	<p>SB 5178 <i>Sponsor(s):</i> Senators Trudeau and Harris</p> <p><i>Pre-filed:</i> 1/8/2025 <i>First Reading (Senate):</i> 1/13/2025, referred to Health & Long-Term Care Committee.</p>

Dead/dormant Bills (relevant if needed to pass the budget)		
Bill # /Companion	Short Title	Bill Summary